Impax Laboratories Inc. Stock Downgraded (IPXL)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Impax Laboratories (Nasdaq: IPXL) has been downgraded by TheStreet Ratings from buy to hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • IPXL's revenue growth has slightly outpaced the industry average of 8.5%. Since the same quarter one year prior, revenues rose by 15.5%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • IPXL has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 3.17, which clearly demonstrates the ability to cover short-term cash needs.
  • 47.30% is the gross profit margin for IMPAX LABORATORIES INC which we consider to be strong. Regardless of IPXL's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, IPXL's net profit margin of 71.00% significantly outperformed against the industry.
  • IMPAX LABORATORIES INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, IMPAX LABORATORIES INC reported lower earnings of $0.81 versus $0.99 in the prior year. For the next year, the market is expecting a contraction of 53.1% in earnings ($0.38 versus $0.81).
  • IPXL has underperformed the S&P 500 Index, declining 23.21% from its price level of one year ago. Turning toward the future, the fact that the stock has come down in price over the past year should not necessarily be interpreted as a negative; it could be one of the factors that may help make the stock attractive down the road. Right now, however, we believe that it is too soon to buy.
.

Impax Laboratories, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and marketing of bioequivalent pharmaceutical products; and development and marketing of branded products. The company has a P/E ratio of 21.3, above the S&P 500 P/E ratio of 17.7. Impax has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are down 15.2% year to date as of the close of trading on Thursday.

You can view the full Impax Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

Impax Shares Jump After Chinese Firm Reveals 5% Stake

Teva, Mylan Seen to Stay on M&A Sidelines

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers